TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nights spent in hospital with a diabetes-related foot problem
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Brain Metastasis Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Wound Volume Reduction Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nerves in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Condition of lipoatrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 27-hydroxycholesterol blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilatory Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Phobia
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline Glycemia at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Insulin at 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Narcotic Requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall valoration
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Impairment (Sheehan Disability Scale)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Disorder-Focused Composite Score (DSM-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sleep and Circadian Function
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Delta VAS pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strain Elastography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Minute Walk Test Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective physical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self reported depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Non-opioid prescription pain medication usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence Rate of Atrial Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hyperactivity Sub-scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Meningitis attack rate
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical performance (sensitivity/specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of prevalence of complementary and alternative therapy use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Geometric mean increases in pneumococcal antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in End Systolic Volume (ESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Medical Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 0 for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cavitated versus non-cavitated caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adverse events up to 21 days after immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with increased levels of immune response (neutralizing antibody titers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changing of virus-neutralizing antibodies to SARS-CoV-2 virus in blood serum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in Yale Brown Obsessive Compulsive Scale for Pathological Gambling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adoption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: De-adoption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Negative Biopsy for Gleason Grade 4 or 5 Prostate Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peripheral arterial augmentation index (Aix)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reactive Hyperemia Index after branchial artery occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assistive Hand Assessment (AHA/miniAHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostatic Specific Antigen (PSA) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with solicited local adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with solicited systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Human Serum Bactericidal Assay Geometric Mean Titers (GMTs) against each of the N. meningitidis serogroup B strains after the second vaccination with rMenB+OMV NZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: success rate of self-instillation eye drops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Sum ST Resolution (STR) 60 Minutes After PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intubation condition score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse from depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mobility disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Penn Craving Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major adverse cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of anti-SARS-CoV-2 Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in clinical attachment level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive energy balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycaemic responses venous blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Capillary glycaemic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abstinence from all tobacco
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Abstinence from smokeless tobacco
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients With Fecal Calprotectin Level ≤ 150 µg/g
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cardiorespiratory fitness (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the frequency of urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evaluation of frequency of urinary tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Efficacy of levetiracetam in treating RLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability and adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma nucleosome concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma free DNA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new decayed surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth weight (BW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (WHOQoL questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in triglycerides in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endomicroscopic features of Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peak Plasma Concentration (CMAX) of nimesulide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of nimesulide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From a Composite of Pre-specified Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Documented Atrial Fibrillation, Atrial Flutter and Atrial Tachycardia Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postoperative Endothelial cell loss of the central corneal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Daily Step Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average change in walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six Minute-Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Human Neutrophil Elastase (HNE) Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall complete spontaneous bowel movement (CSBM) responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treatment Satisfaction with Medicines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Serum Iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Burning sensation and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with laboratory value abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: C-terminal telopeptide crosslinks (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 1 procollagen amino-terminal-propeptide (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Over Basal for Postprandial Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Over Basal for Postprandial Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of unanticipated device and procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Range of motion of elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in the total IPSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability and safety of Staccato Zaleplon
Endpoint domain: Adverse events/effects
Primary endpoint: % change of low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ART durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of screening for CFRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge about HPV risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Success of ERCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sustained viral response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Bipolar Visual Analog Scale (VAS) of Drug Likability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Function/Quality of Life - PVP Group
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Function/Quality of Life - NoPVP group
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depression - PVP group
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression - NoPVP group
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Activation - PVP Group
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Activation - NoPVP Group
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum-tolerated dose of obatoclax mesylate
Endpoint domain: Adverse events/effects
Primary endpoint: SVR (sustained virologic response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in the Ocular Surface Disease Index questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Discontinued Due to Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of an anxiety disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of [18F]FDOPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in MMTT-Stimulated C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number and percentage of participants reporting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of portal pressure (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum WFA+-M2BP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cough-related symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI-aGvHD remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success of a 2-Grade IGA Score Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete Remission Rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose of pembrolizumab with concurrent chemoradiation
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of pembrolizumab with concurrent radiation
Endpoint domain: Adverse events/effects
Primary endpoint: RDQ scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiac output rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Active and passive pain-free shoulder range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acute Stress Measured by Tension
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute Stress Measured by Nervousness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Waist circumference (minimum waist girth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of acromegalic patients with AIP mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of diaphragmatic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Observed Sensitivity Based on Heart Rate Increase Associated With Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modeled Sensitivity Based on Heart Rate Increase Associated With Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Potential False Positives Based on Heart Rate Increase Associated With Seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PANSS-FSNS score for Negative Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted Summed Pain Intensity Difference (SPID-48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Initial Thinking Time for 3-move Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Initial Thinking Time for 5-move Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Between Errors for 6-move Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Strategy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Discrepancy between predicated and actual tooth positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Enrolled With Serum Creatinine >3mg/dL on Postoperative Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients Enrolled Who Require at Least One Session of Dialysis in the First 7 Days Post Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients With Serum Creatinine Reduction Ratio of < 30% From 24 to 48 Hours Post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Dialysis Sessions Per Patient in the First 7 Days Post Transplant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global Longitudinal Left Ventricular (LV) Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen Uptake Efficiency Slope (OUES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Myocardial Blood Flow Reserve (MFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fold Change of Human Beta Defensin2 (hBD2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concordance of cancer detection between liquid and tissue biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Percent Correct in Virtual Reality Visual Field Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin viability assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in the Roland-Morris disability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in the EQ-5D quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Functioning Maximum Capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lower Limb Physical Functioning and Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Handgrip Strength Physical Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmax (Maximal Serum Concentration of Medroxyprogesterone Acetate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time to Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-91 (Area Under Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: RPD Abutment Tooth Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: RPD Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes